FROM 01 Aug, Johnson & Johnson MedTech is withdrawing its non-antibacterial sutures from the ANZ markets, in cases where it can be replaced with an antibacterial alternative.
The move is part of J&J's commitment to help prevent surgical site infections (SSIs), affecting many patients each year.
Healthcare-associated infections are the most common hospital-acquired complications, resulting in $42,102 in extra costs for a single hospitalisation.
SSIs increase morbidity and mortality rates, lead to extended hospital stays, and substantial emotional and physical distress.
Clinicians are recommended to use triclosan-coated Plus Sutures as part of a bundle of care approach, effectively reducing the SSIs risk by 28%.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jun 24
